A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
Gilenya
Recommended Posts
- CMSC 2026: Peer support app may boost confidence after MS diagnosis
- Abnormal fat in brain immune cells may help drive progressive MS
- CMSC 2026: Trial data show frexalimab benefits lasting 3 years
- Our bodies often tell us what we need to know — if we’re willing to listen
- CMSC 2026: MS patients often downplay symptoms to their doctors: Survey